Exclusive Group Acquires Canadian VAD To Expand Presence Across North America
Exclusive Group, the value-added services and technologies (VAST) group, today announced the acquisition of leading Canadian cybersecurity VAD, Fine Tec Canada, to complement its existing US presence and expand global coverage to the whole of North America. The deal coincides with the appointment of Exclusive Group veteran Laurent Daudré-Vignier as SVP North America to oversee and grow operations across the region. Together this enables vendor, GSI and reseller partners with a complete solution for North American value-added distribution services, and boosts the company’s aggressive global growth trajectory.
“Our success in North America to date has been critical to executing our global strategy, and our intention has always been to build on our US presence with the addition of a leading specialist VAD in the Canadian market,” said Olivier Breittmayer, CEO at Exclusive Group. “We are focused on growing our regional presence, and will benefit from Laurent’s outstanding leadership experience in this area. Fine Tec Canada has a strong local reputation for cybersecurity value-added distribution, with a committed and like-minded group of individuals who will be right at home among our team.”
Headquartered in Vancouver, one of Canada’s primary technology centres, Fine Tec Canada operates throughout the country’s vast interior working closely with over 100 reseller partners. Its main vendor partners include Fortinet – a core strategic partner for Exclusive Group. As part of the acquisition, key management including current CEO Jeff Wu – who becomes Country Manager for Exclusive Networks Canada, reporting to Laurent Daudré-Vignier – will remain in their roles to ensure continuity and execute on an accelerated growth plan for the business.
“Exclusive stands apart by demonstrating unique value both within local markets and on a global scale, and I am delighted to head up our enlarged North American operations as we target continued growth across this region,” said Laurent Daudré-Vignier, SVP North America at Exclusive Group. “I look forward to working with the Fine Tec Canada team and bringing them into the Exclusive family. As the 10th largest economy in the world, Canada represents a huge market opportunity for our partner base and we are confident in the success we can achieve over the coming years.”
“This is fantastic news for the Fine Tec Canada team and partner ecosystem, and demonstrates the global attractiveness of our unique VAD proposition,” said Jeff Wu, Founder and CEO at Fine Tec Canada. “In particular, our growing community of reseller partners stands to enjoy significant opportunities arising from access to the wider Exclusive Networks vendor portfolio and comprehensive range of value-based services. We also believe there is huge scope to leverage the worldwide capabilities of the Exclusive Group to win more major international projects.”
The acquisition of Fine Tec Canada comes 18 months after Exclusive Group’s acquisition of its US-based VAD namesake, Fine Tec – a separately owned and staffed organisation, but with similar business models, operating principles and vendor portfolios.
About Exclusive Group
Exclusive Group is building the world’s biggest specialist VAD in cybersecurity and cloud transformation. Through its best-in-class portfolio of market leaders and disruptive challengers, unique reputation for innovative technology expertise, and global services and logistics infrastructure, Exclusive Group creates opportunities across the channel ecosystem by bridging skills gaps in cyber and cloud. With 50+ offices across five continents, and presence in over 100 countries, Exclusive Group is the global value-added services and technologies (VAST) group with a hybrid distribution model that is optimised for volume but differentiated by value. Find out more at www.exclusive-group.com.
About Fine Tec Canada
Fine Tec Canada optimises business for IT security & Network solution vendors, resellers, and their customers—end to end. Starting as a value-added distributor (VAD) in the year 2000, Fine Tec Canada has become the heart of an ecosystem comprised of leading and emerging technology vendors who provide network-security and data-integrity solutions for our broad network of resellers across Canada. We’ve done this by maximising sales opportunities for our partners while removing the hurdles that impede business transactions from before the sale to after the deployment.
+44 (0) 1291 626200
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu
Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX®▼ (daratumumab)19.7.2019 09:59:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of an extension application to the European Medicines Agency (EMA) for subcutaneous (under the skin) use of DARZALEX® (daratumumab) for the treatment of patients with multiple myeloma. This subcutaneous formulation of daratumumab is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) [Halozyme's ENHANZE® drug delivery technology]. Daratumumab is currently only approved for intravenous (IV) use. “This new formulation is an example of our unwavering commitment to pursue innovative treatment options to support people living with multiple myeloma,” said Dr Patrick Laroche, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag. “Importantly, subcutaneous daratumumab demonstrated comparable efficacy with the existing IV formulation, reduced the rate of infusion-related reactions and significantly shortened the time it takes for patients to receive treatment, fr